{"id":449,"date":"2026-08-27T10:31:11","date_gmt":"2026-08-27T10:31:11","guid":{"rendered":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/"},"modified":"2026-08-28T07:42:46","modified_gmt":"2026-08-28T07:42:46","slug":"retatrutide-triple-agonist-phase-2-evidence","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/de\/retatrutide-triple-agonist-phase-2-evidence\/","title":{"rendered":"Retatrutide-Dreifachagonismus: Was die Phase-2-Studie ergab \u2013 und nicht bewies"},"content":{"rendered":"

Retatrutide wurde entwickelt, um die GIP-, GLP-1- und Glucagonrezeptoren in einem Molek\u00fcl zu aktivieren. Die 2023-Phase der 2-Fettleibigkeitsstudie stie\u00df auf gro\u00dfes Interesse, aber die richtige Interpretation h\u00e4ngt von der Versuchsphase, der Population, den Endpunkten, den Ergebnissen unerw\u00fcnschter Ereignisse und dem, was unbekannt blieb, ab.<\/p>

Wichtige Erkenntnisse<\/h2>
  • Retatrutide ist ein einzelnes Pr\u00fcfmolek\u00fcl mit Aktivit\u00e4t an drei Hormonrezeptoren.<\/li>
  • Die h\u00e4ufig zitierten Ergebnisse stammen aus einer 338-Teilnehmerphase der 2-Studie und nicht aus einer Zulassungsentscheidung.<\/li>
  • Der Abschluss der Phase-3-Studie bedeutet nicht, dass Ergebnisse ver\u00f6ffentlicht oder ein Produkt zugelassen werden.<\/li><\/ul><\/div><\/div>
    \"Forscher
    Urspr\u00fcngliche redaktionelle Illustration von drei Rezeptor-Signalwegen in einem Forschungslabor; keine Darstellung der klinischen Verabreichung.<\/figcaption><\/figure>

    Das Drei-Rezeptoren-Konzept<\/h2>

    Retatrutide, in Entwicklungsunterlagen auch als LY3437943 identifiziert, ist ein Agonist an GIP-, GLP-1- und Glucagonrezeptoren. Die Bezeichnung \u201edreifacher Agonist\u201c beschreibt die Pharmakologie des Rezeptors; Es allein sagt nicht das Ausma\u00df, die Dauerhaftigkeit oder die Sicherheit eines Ergebnisses in einer bestimmten Bev\u00f6lkerungsgruppe voraus.<\/p>

    Das Aktivit\u00e4tsgleichgewicht zwischen den drei Rezeptoren, das Expositionsprofil des Molek\u00fcls und die untersuchte Formulierung tragen alle zu den beobachteten Wirkungen bei.<\/p>

    Was die Phase-2-Studie gemessen hat<\/h2>

    An der randomisierten, doppelblinden, placebokontrollierten Studie nahmen 338-Erwachsene mit Fettleibigkeit oder \u00dcbergewicht und einer gewichtsbedingten Erkrankung teil. Der prim\u00e4re Endpunkt war die prozentuale Ver\u00e4nderung des K\u00f6rpergewichts nach 24 Wochen; 48-Wochenver\u00e4nderung und kategoriale Gewichtsreduktionsschwellenwerte waren sekund\u00e4re Endpunkte. Magen-Darm-Erkrankungen waren die h\u00e4ufigsten unerw\u00fcnschten Ereignisse und es wurde ein dosisabh\u00e4ngiger Anstieg der Herzfrequenz beobachtet, der im weiteren Verlauf der Studie jedoch abnahm.<\/p>

    Die Studie ermittelte ein Dosis-Wirkungs-Signal und unterst\u00fctzte die 3-Entwicklungsphase. Es konnte kein langfristiges Nutzen-Risiko-Verh\u00e4ltnis f\u00fcr breitere Bev\u00f6lkerungsgruppen, keine direkte \u00dcberlegenheit gegen\u00fcber jeder Alternative oder eine Gleichwertigkeit zwischen Versuchsmaterial und einem Katalogprodukt festgestellt werden.<\/p>

    Design<\/strong>Randomisierte, doppelblinde, placebokontrollierte Phase-2-Studie<\/span><\/div>
    Teilnehmer<\/strong>338 Erwachsene<\/span><\/div>
    Dauer<\/strong>48 Wochen<\/span><\/div>
    Schl\u00fcsselgrenze<\/strong>Ermittlungsbeweise, keine FDA-Genehmigung<\/span><\/div><\/div><\/div>

    Was sich durch 2026 ge\u00e4ndert hat<\/h2>

    ClinicalTrials.gov listet TRIUMPH-1 als eine abgeschlossene Phase-3-Studie auf, wobei die Studie im April 2026 abgeschlossen wurde und in dem f\u00fcr diesen Artikel \u00fcberpr\u00fcften Datensatz keine Ergebnisse ver\u00f6ffentlicht wurden. \u201eAbgeschlossen\u201c beschreibt den Studienstatus; Es ersetzt nicht Ergebnisse, Peer-Reviews oder beh\u00f6rdliche Bewertungen.<\/p>

    In den aktuellen \u00f6ffentlichen Informationen von FDA hei\u00dft es, dass Retatrutid kein Bestandteil eines von FDA zugelassenen Medikaments ist. In einem korrekten 2026-Artikel sollte es daher als Untersuchungsgegenstand beschrieben werden, es sei denn und bis in einem ma\u00dfgeblichen Genehmigungsprotokoll etwas anderes angegeben ist.<\/p>

    Von 2026 gesponserte Phase 3-Oberlinie<\/h2>

    Lilly berichtete im Mai \u00fcber Topline-Ergebnisse f\u00fcr TRIUMPH-1. 21, 2026: In den 80-Wochen meldete der Sponsor eine durchschnittliche Gewichtsver\u00e4nderung von \u221228.3% f\u00fcr die 12-mg-Gruppe. Im Juli berichteten 23, 2026, Lilly mittlere \u00c4nderungen bis zu \u221220.8% in TRIUMPH-2 und \u221222.6% in TRIUMPH-3. Hierbei handelt es sich um Offenlegungen von Hauptsponsoren, nicht um Ergebnismodule von ClinicalTrials.gov oder vollst\u00e4ndige, von Experten \u00fcberpr\u00fcfte Berichte. F\u00fcr detaillierte Methoden, Analyseentscheidungen und vollst\u00e4ndige Tabellen zu unerw\u00fcnschten Ereignissen sind weiterhin vollst\u00e4ndige Aufzeichnungen erforderlich. ClinicalTrials.gov zeigte bei dieser \u00dcberpr\u00fcfung weiterhin \u201eKeine Ergebnisse ver\u00f6ffentlicht\u201c f\u00fcr TRIUMPH-1 an.<\/p>","protected":false},"excerpt":{"rendered":"

    Eine genaue Lekt\u00fcre der Pharmakologie der GIP-, GLP-1- und Glucagonrezeptor-Rezeptoren von Retatrutid sowie der 48-Wochenphase-Adipositasstudie 2, einschlie\u00dflich Einschr\u00e4nkungen und aktuellem Forschungsstatus.<\/p>","protected":false},"author":1,"featured_media":619,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"359","pim_article_type":"Clinical trial evidence review","pim_evidence_level":"Randomized phase 2 human trial; investigational status","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-28","pim_editorial_note":"Source-checked against the linked primary or authoritative records on 2026-08-27. This is an evidence summary, not independent peer review, medical advice or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"Triple-Hormone-Receptor Agonist Retatrutide for Obesity \u2014 phase 2 trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37366315\/\",\"note\":\"Primary randomized phase 2 record; PMID 37366315.\"},{\"title\":\"TRIUMPH-1 phase 3 study record\",\"url\":\"https:\/\/clinicaltrials.gov\/study\/NCT05929066\",\"note\":\"ClinicalTrials.gov record updated June 2026; results not posted in the reviewed record.\"},{\"title\":\"FDA information on unapproved GLP-1 products\",\"url\":\"https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss\",\"note\":\"Current regulatory-status boundary.\"},{\"title\":\"TRIUMPH-1 sponsor-reported topline results\",\"url\":\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss\",\"note\":\"Lilly primary-sponsor news release, May 21, 2026; not a peer-reviewed full report.\"},{\"title\":\"TRIUMPH-2 and TRIUMPH-3 sponsor-reported topline results\",\"url\":\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-successful-two-additional\",\"note\":\"Lilly primary-sponsor news release, July 23, 2026; detailed results remain pending.\"}]","footnotes":""},"categories":[18],"tags":[],"class_list":["post-449","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-reviews"],"yoast_head":"\nRetatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove - NHD<\/title>\n<meta name=\"description\" content=\"A close reading of retatrutide\u2019s GIP, GLP-1 and glucagon receptor pharmacology and the 48-week phase 2 obesity trial, including limitations and current investigational status.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/de\/retatrutide-triple-agonist-phase-2-evidence\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove\" \/>\n<meta property=\"og:description\" content=\"A close reading of retatrutide\u2019s GIP, GLP-1 and glucagon receptor pharmacology and the 48-week phase 2 obesity trial, including limitations and current investigational status.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/de\/retatrutide-triple-agonist-phase-2-evidence\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T10:31:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:42:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:42:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/\"},\"wordCount\":444,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp\",\"articleSection\":[\"Evidence Reviews\"],\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/\",\"name\":\"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:42:46+00:00\",\"description\":\"A close reading of retatrutide\u2019s GIP, GLP-1 and glucagon receptor pharmacology and the 48-week phase 2 obesity trial, including limitations and current investigational status.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/de\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Retatrutide-Dreifachagonismus: Was die Phase-2-Studie ergab \u2013 und nicht bewies \u2013 NHD","description":"Eine genaue Lekt\u00fcre der Pharmakologie der GIP-, GLP-1- und Glucagonrezeptor-Rezeptoren von Retatrutid sowie der 48-Wochenphase-Adipositasstudie 2, einschlie\u00dflich Einschr\u00e4nkungen und aktuellem Forschungsstatus.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/de\/retatrutide-triple-agonist-phase-2-evidence\/","og_locale":"de_DE","og_type":"article","og_title":"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove","og_description":"A close reading of retatrutide\u2019s GIP, GLP-1 and glucagon receptor pharmacology and the 48-week phase 2 obesity trial, including limitations and current investigational status.","og_url":"https:\/\/nhdbio.com\/de\/retatrutide-triple-agonist-phase-2-evidence\/","og_site_name":"NHD","article_published_time":"2026-08-27T10:31:11+00:00","article_modified_time":"2026-08-28T07:42:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Verfasst von":"NHD Technical Team","Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:42:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/"},"wordCount":444,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp","articleSection":["Evidence Reviews"],"inLanguage":"de","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/","url":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/","name":"Retatrutide-Dreifachagonismus: Was die Phase-2-Studie ergab \u2013 und nicht bewies \u2013 NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:42:46+00:00","description":"Eine genaue Lekt\u00fcre der Pharmakologie der GIP-, GLP-1- und Glucagonrezeptor-Rezeptoren von Retatrutid sowie der 48-Wochenphase-Adipositasstudie 2, einschlie\u00dflich Einschr\u00e4nkungen und aktuellem Forschungsstatus.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Peptidrohstoffe und individuelle Peptidsynthese","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"NHD Technisches Team","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"Das technische Team von NHD verwaltet Katalogdokumentationen und Beweiszusammenfassungen f\u00fcr Forschungszwecke. Rezensierte Artikel verweisen auf von Experten begutachtete Artikel, Studienregister und beh\u00f6rdliche Aufzeichnungen, behalten Nullergebnisse und Studieneinschr\u00e4nkungen bei und unterscheiden ver\u00f6ffentlichte Interventionen von Katalogmaterialien. F\u00fcr die Strukturierung kann AI-unterst\u00fctztes Zeichnen verwendet werden; Quellenverkn\u00fcpfungen und Beweisgrenzen bleiben sichtbar. Bei dieser Arbeit handelt es sich nicht um eine unabh\u00e4ngige Begutachtung oder medizinische Beratung.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/de\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts\/449","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/comments?post=449"}],"version-history":[{"count":2,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts\/449\/revisions"}],"predecessor-version":[{"id":528,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts\/449\/revisions\/528"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/media\/619"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/media?parent=449"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/categories?post=449"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/tags?post=449"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}